OmniAb Q4 revenue falls 22%, misses expectations

OmniAB

04/03/2026 21:28

Overview

Biotech platform's Q4 revenue fell 22% yr/yr, missing analyst expectations

Net loss for Q4 increased to $14.2 mln from $13.1 mln yr/yr

Company entered new license agreements, including with Dana Farber Cancer Institute

Outlook

OmniAb expects 2026 revenue between $25 mln and $30 mln

Company forecasts 2026 operating expenses between $80 mln and $85 mln

OmniAb anticipates ending 2026 with cash and equivalents of $30 mln to $35 mln

Result Drivers

REVENUE DECLINE - Q4 revenue decreased due to lower license and service revenue, partially offset by milestone and royalty revenue increases

NEW TECHNOLOGY LAUNCH - Launch of OmniUltra and interest in xPloration program contributed to business growth

Company press release: ID:nBw4gkhFpa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$8.4 mln
$9.003 mln (7 Analysts)
Q4 EPS
-$0.11
Q4 Net Income
-$14.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for OmniAb Inc is $8.00, about 362.4% above its March 3 closing price of $1.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)